Announcement on Subsidiary Companies Obtaining Drug Registration Approval
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Sharp Group No.: Pro 2019-007
Bond Abbreviation: 13 Spike 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Registration Approval
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Registration Approval Document" (Approval No.: 2019S00296) of olopatadine hydrochloride eye drops approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of
1. Drugs
Drug Name: Olopatadine Hydrochloride Eye Drops
Dosage Form: Ophthalmic Preparation
Specification: 0.1 (5ml:5mg, based on C 21 H 23 NO 3 )
Application Items: Domestic Drug Registration
Registration Classification: Chemical Drug Class 4
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Acceptance Number: CYHS1600042 Zhejiang
batch number: 2019S00296
drug standard number: YBH00792019
drug validity period: 36 months
drug approval number: national drug H20193095
drug approval number validity period: until April 02, 2024
approval conclusion: according to the "the People's Republic of China Drug Administration Law" and relevant regulations, after examination, this product meets the relevant requirements of drug registration, approves the registration, and issues the drug approval number.
Other relevant conditions of 2. drug
This drug is used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1- receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments.
Olopatadine Hydrochloride Eye Drops has been included in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) and classified as Class B; it is not included in the National Essential Drugs List (2018 Edition). At present, Novartis Europharm Limited, towering pharmaceutical (China) co., ltd., Jiangsu hanchen pharmaceutical co., ltd., Jiangxi kelun pharmaceutical co., ltd., Guangdong hongying technology co., ltd., Qilu pharmaceutical co., ltd. and Shenyang xingqi ophthalmic co., ltd. olopatadine hydrochloride eye drops have been approved for listing in China. After querying the IMS database, global sales of olopatadine hydrochloride eye drops in 2018 were approximately US $0.37 billion and China sales were approximately US $10.232 million.
Up to now, the research and development investment of spiking pharmaceutical olopatadine hydrochloride eye drops project is about 660 yuan. The impact of
3. on the company
Jianfeng Pharmaceutical already has a corresponding production line. This time, it has obtained the Drug Registration Approval Document of olopatadine hydrochloride eye drops, which indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug. It will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business.
4. Risk Warning
Company attaches great importance to the quality and safety of drug research and development, manufacturing and sales. However, due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the early stage of drug research and development, approval to production has a long cycle, large investment and many links, moreover, the production and sales of drugs after obtaining approval are also vulnerable to national policies, market environment and other factors. Please the majority of investors cautious decision-making, pay attention to prevent investment risk.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 17, 2019
More information
Representatives of the 20th Congress preached the 20th Congress at the peak.
On the afternoon of November 11, a special lecture on the spirit of the Party's 20th Congress was held in the conference room of the Peak Building. Yang Xiayun, a representative of the 20th National Congress, walked into the peak and preached his understanding of the spirit of the 20th National Congress for Party members through personal experience.
2022
11-23
The group party committee organizes and learns the twenty spirits.
On the afternoon of October 28, the party Committee of the group organized all members to hold a special study meeting to earnestly study and understand the communique of the first plenary session of the 20th central Committee of the communist party of China and the revision of the party constitution. Jiang Xiaomeng, Secretary of the Party committee of the group, stressed at the study meeting that the 20th National Congress of the Communist Party of China has drawn a grand blueprint for building a socialist modern country in an all-round way, opened a new chapter in the era of national development, and pointed out the direction for the future development of enterprises. Party organizations at all levels of the group should pay full attention to and earnestly implement it, actively organize party members and cadres to learn the spirit of the spirit of the 20th National Congress, And to guide the future work practice.
2022
11-01
Spike Party Members and Cadres Watch the Opening Meeting of the 20th Congress
At 10 a.m. on October 16, the 20th National Congress of the Communist Party of China was solemnly opened in the Great Hall of the People in Beijing. Xi Jinping delivered a report to the Party's 20th National Congress on behalf of the 19th Central Committee. The group company attaches great importance to and carefully deploys, and organizes all party members and management backbones of the group headquarters and subsidiaries to watch the live broadcast of the opening meeting through the Internet, TV and other methods.
2022
10-23
Jiang Xiaomeng was hired as the "Shuanglong Escort" entrepreneurial mentor.
On September 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, was employed as the entrepreneurial mentor of "Shuanglong escort" at the launching ceremony of the special action of "Shuanglong escort steady progress and quality improvement" held in Jinhua City and the promotion meeting of innovative products of key talent enterprises in Jinhua City.
2022
09-27
From August 18th to 19th, the 12th Congress of the Zhejiang Federation of Industry and Commerce was held in Hangzhou, and the 12th leadership of the Provincial Federation of Industry and Commerce was elected. Jiang Xiaomeng, Secretary of the Party Committee and Chairman of the Group, was re-elected as Vice President of Zhejiang Chamber of Commerce.
2022
09-01
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page